Design of non-cytotoxic 6,7-dihydroxycoumarin-5-carboxylates with antibiofilm activity against Staphylococcus aureus and Candida albicans.

The 6,7-dihydroxycoumarin-5-carboxylates DHCou and 4-Me-DHCou have been synthesized via five-step route including a propargyl-Claisen rearrangement as key step. The compounds show antibiofilm activity against Stapylococcus aureus and Candida albicans but lack the cytotoxic activity of parent 6,7-dihydroxycoumarines such as esculetin and 4-methylesculetin.

Extending the Structure-Activity Relationship of Disorazole C1 : Exchanging the Oxazole Ring by Thiazole and Influence of Chiral Centers within the Disorazole Core on Cytotoxicity.

The synthesis of novel disorazole C1 analogues is described and their biological activity as cytotoxic compounds is reported. Based on our convergent entry to the disorazole core we present a flexible and robust strategy to construct a variety of interesting new analogues. In particular, two regions of the molecules were examined for structural modification: 1. Replacement of the heterocyclic moiety by an exchange of the oxazole ring by a thiazole; and 2. Evaluation of the influence of the absolute configuration of the chiral centers of the molecule. Predicated on our flexible strategy we were able to construct all analogues in an efficient way and could perform an exciting SAR (structure-activity-relationship) study to obtain insight in the cytotoxic activity influenced by the chiral centers of the disorazole core.

The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates.

The concept of targeted drug conjugates has been successfully translated to clinical practice in oncology. Whereas the majority of cytotoxic effectors in drug conjugates are directed against either DNA or tubulin, our study aimed to validate nuclear export inhibition as a novel effector principle in drug conjugates. For this purpose, a semisynthetic route starting from the natural product ratjadone A, a potent nuclear export inhibitor, has been developed. The biological evaluation of ratjadones functionalized at the 16-position revealed that oxo- and amino-analogues had very high potencies against cancer cell lines (e.g. 16R-aminoratjadone 16 with IC50 = 260 pM against MCF-7 cells, or 19-oxoratjadone 14 with IC50 = 100 pM against A-549 cells). Mechanistically, the conjugates retained a nuclear export inhibitory activity through binding CRM1. To demonstrate a proof-of-principle for cellular targeting, folate- and luteinizing hormone releasing hormone (LHRH)-based carrier molecules were synthesized and coupled to aminoratjadones as well as fluorescein for cellular efficacy and imaging studies, respectively. The Trojan-Horse conjugates selectively addressed receptor-positive cell lines and were highly potent inhibitors of their proliferation. For example, the folate conjugate FA-7-Val-Cit-pABA-16R-aminoratjadone had an IC50 of 34.3 nM, and the LHRH conjugate d-Orn-Gose-Val-Cit-pABA-16R-aminoratjadone had an IC50 of 12.8 nM. The results demonstrate that nuclear export inhibition is a promising mode-of-action for extracellular-targeted drug conjugate payloads.

New, non-quinone fluorogeldanamycin derivatives strongly inhibit Hsp90.

Streptomyces hygroscopicus is a natural producer of geldanamycin. Mutasynthetic supplementation of an AHBA-blocked mutant with all possible monofluoro 3-aminobenzoic acids provided new fluorogeldanamycins. These showed strong antiproliferative activity and inhibitory effects on human heat shock protein Hsp90. Binding to Hsp90 in the low nanomolar range was determined from molecular modelling, AFM analysis and by calorimetric studies.

Preparation of thermocleavable conjugates based on ansamitocin and superparamagnetic nanostructured particles by a chemobiosynthetic approach.

A combination of mutasynthesis, precursor-directed biosynthesis and semisynthesis provides access to new ansamitocin derivatives including new nanostructured particle-drug conjugates. These conjugates are based on the toxin ansamitocin and superparamagnetic iron oxide-silica core shell particles. New ansamitocin derivatives that are functionalized either with alkynyl- or azido groups in the ester side chain at C-3 are attached to nanostructured iron oxide core-silica shell particles. Upon exposure to an oscillating electromagnetic field these conjugates heat up and the ansamitocin derivatives are released by a retro-Diels-Alder reaction. For example, one ansamitocin derivative exerts strong antiproliferative activity against various cancer cell lines in the lower nanomolar range while the corresponding nanostructured particle-drug conjugate is not toxic. Therefore, these new conjugates can serve as dormant toxins that can be employed simultaneously in hyperthermia and chemotherapy when external inductive heating is applied.

Bioreduction of aryl azides during mutasynthesis of new ansamitocins.

Supplementing a culture of a mutant strain of Actinosynnema pretiosum that is unable to biosynthesize aminohydroxy benzoic acid (AHBA), with 3-azido-5-hydroxy-benzoic acid and 3-azido-5-amino-benzoic acid, unexpectedly yielded anilino ansamitocins instead of the expected azido derivatives. This is the first example of the bioreduction of organic azides. The unique nature of these results was demonstrated when 3-azido-5-amino-benzoic acid was fed to the corresponding AHBA blocked mutant of Streptomyces hygroscopicus, the geldanamycin producer. This mutasynthetic experiment yielded the fully processed azido derivative of geldanamycin.

Unprecedented deoxygenation at C-7 of the ansamitocin core during mutasynthetic biotransformations.

We describe the unprecedented formation of six ansamitocin derivatives that are deoxygenated at C-7 of the ansamitocin core, obtained during fermentation experiments by employing a variety of Actinosynnema pretiosum mutants and mutasynthetic approaches. We suggest that the formation of these derivatives is based on elimination at C-7/C-8 followed by reduction(s) of the intermediate enone. In bioactivity tests, only ansamitocin derivatives bearing an ester side chain at C-3 showed strong antiproliferative activity.

Heterologous hyper-expression of a glucansucrase-type glycosyltransferase gene.

Heterologous expression of the large glucansucrase-type glycosyltransferases genes is still a challenge, and typically yields are poor. Therefore, a number of different Escherichia coli systems for the expression of such a gene, encoding the glycosyltransferase R (GtfR) from Streptococcus oralis, were constructed and evaluated. We thereby obtained a strain producing the highest molar yields described so far for this class of enzymes. Cloning of a 5'-terminally truncated version of the gene in the expression vector pET33b(+) yielded, in dissolved form, about 2 micromol (300 mg) of enzyme per liter of culture of an optical density at 600 nm of four. Problems frequently encountered in the heterologous biosynthesis of this class of enzymes, such as formation of a high fraction of insoluble aggregates and/or proteolytic degradation, were not observed in the described system. The over-produced enzyme, devoid of almost its entire variable region, retained its characteristic activities.

Re- or displacement of invariant residues in the C-terminal half of the catalytic domain strongly affects catalysis by glucosyltransferase R.

It is shown that exchanges of single invariant amino acids in two C-terminal catalytic domain segments of the glucosyltransferase R (GtfR) strongly affect its catalytic properties. Drastic decreases of activity through re- or displacements of Tyr965 demonstrate a crucial role of this residue. Similarly, exchanges of amino acids Asp1004, Val1006, and Tyr1011 profoundly influenced catalytic parameters. These results are interpreted on the basis of a homology model of the catalytic domain. They are consistent with the view that Tyr965 is a constituent of the substrate-binding pocket and directly contacts the sucrose molecule, whereas the other critical residues contribute to the required positioning of Tyr965 and other active site residues.

Identification of structural determinants for substrate binding and turnover by glucosyltransferase R supports the permutation hypothesis.

Segments that may crucially influence the catalytic behaviour of glucosyltransferases of the glucansucrase type were selected for modification. This was done by sequence alignments, followed by structural modelling of the putative catalytic domain, based on a permuted form of the glucosyltransferase R (GtfR) of Streptococcus oralis. Five selected regions, located in the C-terminal half of the potential catalytic domain, were replaced by segments found at equivalent positions in other glucosyltransferases. The exchanges of four of these regions significantly affected catalysis by GtfR. This identified C-terminal determinants for substrate binding and turnover and supports the so-called permutation hypothesis with respect to enzymes of the glucansucrase type. Based on the model, roles are proposed for specific residues. Major effects appear to involve a re-positioning of the C-terminal Tyr965 that very likely serves as a hydrophobic platform for the substrate.